Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Leukodystrophy as a feature of PIGT-CDG

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differences in distribution and regulation of astrocytic aquaporin-4 in human and rat hydrocephalic brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Advances in Research on Human Meningiomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Isolated Ocular Sarcoidosis Mimicking Ring Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • L P Priesterbach-Ackley
  • H B Boldt
  • J K Petersen
  • N Bervoets
  • D Scheie
  • B P Ulhøi
  • M Gardberg
  • T Brännström
  • S H Torp
  • E Aronica
  • B Küsters
  • W F A den Dunnen
  • F Y F L de Vos
  • P Wesseling
  • W W J de Leng
  • B W Kristensen
Vis graf over relationer

AIMS: Methylation profiling (MP) is increasingly incorporated in the diagnostic process of central nervous system (CNS) tumours at our centres in The Netherlands and Scandinavia. We aimed to identify the benefits and challenges of MP as a support tool for CNS tumour diagnostics.

METHODS: About 502 CNS tumour samples were analysed using (850 k) MP. Profiles were matched with the DKFZ/Heidelberg CNS Tumour Classifier. For each case, the final pathological diagnosis was compared to the diagnosis before MP.

RESULTS: In 54.4% (273/502) of all analysed cases, the suggested methylation class (calibrated score ≥0.9) corresponded with the initial pathological diagnosis. The diagnosis of 24.5% of these cases (67/273) was more refined after incorporation of the MP result. In 9.8% of cases (49/502), the MP result led to a new diagnosis, resulting in an altered WHO grade in 71.4% of these cases (35/49). In 1% of cases (5/502), the suggested class based on MP was initially disregarded/interpreted as misleading, but in retrospect, the MP result predicted the right diagnosis for three of these cases. In six cases, the suggested class was interpreted as 'discrepant but noncontributory'. The remaining 33.7% of cases (169/502) had a calibrated score <0.9, including 7.8% (39/502) for which no class indication was given at all (calibrated score <0.3).

CONCLUSIONS: MP is a powerful tool to confirm and fine-tune the pathological diagnosis of CNS tumours, and to avoid misdiagnoses. However, it is crucial to interpret the results in the context of clinical, radiological, histopathological and other molecular information.

OriginalsprogEngelsk
TidsskriftNeuropathology and Applied Neurobiology
Vol/bind46
Udgave nummer5
Sider (fra-til)478-492
Antal sider15
ISSN0305-1846
DOI
StatusUdgivet - aug. 2020

Bibliografisk note

© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

ID: 62326767